The latest trading day saw Gilead Sciences (GILD) settling at $92.96, representing a +1.22% change from its previous close.

We recently published a list of Billionaire Steve Cohen’s Top 15 Stock Picks. In this article, we are going to take a look at ...

The global precision diagnostics and medicine market, valued at US$132.46 billion in 2023, is forecasted to grow at a robust CAGR of 11.1%, reaching US$145.53 billion in 2024 and an impressive US$246.

Global leaders must urgently prioritise and work to provide access to new long-acting HIV prevention -- and potentially ...

The global precision diagnostics and medicine market, valued at US$132.46 billion in 2023, is forecasted to grow at a robust CAGR of ...

So far, the FDA has approved the drug only for people who already have HIV that’s resistant to other treatments. But its ...

UNAIDS urges speed and compassion urging pharmaceutical companies to enable access to new, life-saving medicines DAVOS/GENEVA, 21 January 2025—Today, at the World Economic Forum’s annual meeting in ...

It’s all the more tragic because HIV drugs can keep people from catching the virus, and prevent those living with the virus from passing it on. If everyone who needed these drugs could access them, ...

Zacks Research boosted their Q2 2025 earnings per share estimates for Gilead Sciences in a report issued on Thursday, January ...

GILD has performed well in the past six months, with new drug approvals, positive data readouts and strong quarterly results.